Thrombosis News and Research

Latest Thrombosis News and Research

ACC report helps clinicians optimize appropriate use of noninvasive vascular tests

A new report issued today by the American College of Cardiology (ACC) and developed in collaboration with 10 other leading professional societies provides detailed criteria to help clinicians optimize the appropriate use of certain noninvasive vascular tests when caring for patients with known or suspected disorders of the venous (veins) system.

20 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Protein that triggers blood clotting plays critical role in growth of pancreatic and breast cancer

A recently discovered form of the protein that triggers blood clotting plays a critical role in promoting the growth of metastatic pancreatic cancer and primary breast cancer, according to the cumulative findings from two new scientific manuscripts published online ahead of print in the International Journal of Cancer and PNAS (Proceedings of the National Academy of Sciences).

12 Jul 2013

UIC researchers help minority patients to manage their health with common blood thinner

Minority patients trying to self-manage their health with the blood-thinning drug warfarin face difficulties, and researchers at the University of Illinois at Chicago College of Pharmacy are trying to help overcome them.

12 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.

11 Jul 2013

Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

Emmanouil S. Brilakis, M.D., Ph.D., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, and colleagues conducted a review of medical literature regarding optimal medical therapy after percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries).

10 Jul 2013

CorMedix's Neutrolin catheter lock solution receives CE Mark approval

CorMedix Inc. today announced that it has received CE Mark approval for Neutrolin, a catheter lock solution, for patients with central venous catheters on hemodialysis secondary to advanced chronic kidney disease.

6 Jul 2013

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Baxter International Inc. today announced data featuring ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a leading recombinant treatment available worldwide, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands.

From Baxter International Inc. 5 Jul 2013

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen Idec nd Swedish Orphan Biovitrum AB (publ) presented new data that support the clinical and safety profile of their long-lasting recombinant factor VIII candidate ELOCTATE for hemophilia A.

4 Jul 2013

Expertly written, practical handbook of pediatric thrombosis and hemostasis

An expertly written, practical handbook for the clinical assessment and management of children with inherited or acquired bleeding and clotting disorders

4 Jul 2013

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Biogen Idec and Swedish Orphan Biovitrum AB (publ) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis Congress in Amsterdam, The Netherlands.

3 Jul 2013

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders.

2 Jul 2013

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.

2 Jul 2013

DNA fragments in blood may help doctors to quickly identify coronary artery disease

DNA fragments in your blood may someday help doctors quickly learn if chest pain means you have narrowed heart arteries, according to a new study published in the American Heart Association journal Arteriosclerosis, Thrombosis, and Vascular Biology.

2 Jul 2013

Mount Sinai cardiologist receives AHA/ASA Ron Haddock International Impact Award

The American Heart Association (AHA) has awarded world-renowned cardiologist Dr. Valentin Fuster, MD, PhD, Director of Mount Sinai Heart at The Mount Sinai Medical Center, its prominent American Heart Association/American Stroke Association Ron Haddock International Impact Award.

28 Jun 2013

Orlando Health's clinicians provide hospital-level care in patient's home

Instead of admitting patients to medical units at the hospital, clinicians at Orlando Regional Medical Center are providing health care to patients in the comfort of their homes. The new twist on modern medicine is being piloted in a project to provide hospital-level care in a patient's home through home visits, videoconferencing (virtual visit) and telemonitoring (remote vital signs monitoring).

28 Jun 2013

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

28 Jun 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

Th17 lymphocyte: The master coordinator of cellular inflammation in vessel wall

Every year, more than 16,000 Americans die as a result of what's known as an "aortic dissection" - a catastrophic rupture of the aorta, the body's largest artery. Once thought to be a simple structural failure, aortic dissection is now understood to be caused by an inflammatory process that weakens the artery's walls.

21 Jun 2013

Thrombosis News and Research

Latest Thrombosis News and Research

ACC report helps clinicians optimize appropriate use of noninvasive vascular tests

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Protein that triggers blood clotting plays critical role in growth of pancreatic and breast cancer

UIC researchers help minority patients to manage their health with common blood thinner

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

CorMedix's Neutrolin catheter lock solution receives CE Mark approval

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Expertly written, practical handbook of pediatric thrombosis and hemostasis

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

DNA fragments in blood may help doctors to quickly identify coronary artery disease

Mount Sinai cardiologist receives AHA/ASA Ron Haddock International Impact Award

Orlando Health's clinicians provide hospital-level care in patient's home

Janssen receives complete response letter from FDA for XARELTO sNDA

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Th17 lymphocyte: The master coordinator of cellular inflammation in vessel wall

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Thrombosis News and Research

Latest Thrombosis News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in